Cite
HARVARD Citation
Chaparro, M. et al. (n.d.). OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT). Journal of Crohn's and colitis. pp. i50-i54. [Online].